Altis Labs Launches Digital Twins for Clinical Trials with AstraZeneca and Bayer

Our portfolio company, Altis Labs has announced an international coalition focused on the development and implementation of digital twins in clinical trials with AstraZeneca and Bayer Pharmaceuticals.

Digital twins are simulations that help drug developers and clinicians understand how a patient and/or a therapy may perform in real-life situations. Altis, which develops AI-supported computational imaging to accelerate clinical trials, will contribute its Nota imaging platform that manages and analyzes imaging data from previous and current clinical trials using prognostic AI models

Clinical trials are crucial to help inform the effectiveness of therapies and also biological insights that further support our understanding of the underlying disease. It’s our responsibility to act on that insight and prioritize bringing the knowledge to the clinical and research community, as soon as possible. Advanced AI-based patient models such as digital twins will contribute to increasing the insight generated from clinical trial data.

said Guenter Schmidt, Vice President of Image Data Sciences at AstraZeneca.

This initiative seeks to transform clinical trial design by speeding up timelines and reducing failure rates associated with bringing novel, efficacious cancer treatments to patients in need.

With a track record of building and operationalizing the world’s largest real-world cancer imaging database for AI research in collaboration with Canada’s top cancer centers and leading biopharma sponsors, we’re excited to leverage our cutting-edge AI tools to help improve patient outcomes,

said Felix Baldauf-Lenschen, Founder and CEO of Altis.

Access to their full press release here